NCT06359509View on ClinicalTrials.gov

Study of SYS6020 in BCMA-positive Multiple Myeloma

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2032

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

BCMA Targeted CAR T-cells

Each patient will receive BCMA Targeted CAR T-cells by intravenous infusion.

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT06359509 - Study of SYS6020 in BCMA-positive Multiple Myeloma | Biotech Hunter | Biotech Hunter